Australia markets open in 3 hours 3 minutes

    -79.20 (-1.02%)

    +0.0042 (+0.58%)
  • ASX 200

    -76.30 (-1.03%)
  • OIL

    +1.07 (+1.25%)
  • GOLD

    +30.80 (+1.70%)

    -243.28 (-0.42%)
  • CMC Crypto 200

    -0.00 (-0.00%)

2021 Diabetes Care Intelligence Center Database -

·4-min read

DUBLIN, December 06, 2021--(BUSINESS WIRE)--The "Diabetes Care Intelligence Center" report has been added to's offering.

This report is a global intelligence database on diabetes drugs & devices, which offers data on 25 major countries.

It covers 13 years of comparable data, including 5-year forecasts incorporating value, volume sales, and price and price per-capita expenditure. The Intelligence Centre enhances your understanding of the diabetes drugs industry, along with economic factors impacting diabetes drug usage, such as diabetes population, Type 1 and Type 2 Diabetic population, and obesity, which provide you with actionable business insights.

Market Scope

  • Diabetes drugs & devices market data, volume and value analytics with growth trends (2012-2023)

  • Branded & generic drugs and devices' sales data from 2012-2023

  • Segment, sub-segment & company devices' sales data from 2012-2023

  • Additional information includes - diabetic population levels, diabetes prevalence, Diabetes Type 1 population, Diabetes Type 2 population, and per-capita expenditure.

Companies Mentioned

  • Abbott Diabetes Care

  • Acon

  • Agamatrix Inc.

  • Arkray

  • Ascensia Diabetes Care

  • Astellas

  • AstraZeneca

  • Bionime Corporation

  • Boehringer Ingelheim

  • Bristol Myers Squibb

  • Dexcom

  • Eli Lilly

  • Janssen Pharmaceuticals

  • Johnson & Johnson

  • Medisana

  • Medtronic

  • Merck and Co.

  • Novartis

  • Novo Nordisk

  • Pfizer

  • Roche

  • Rossmax

  • Sanofi

  • Takeda

  • Trivida

Diabetes Drug Categories:

  • Insulin

  • Basal Insulin or Long-acting Insulin

  • Bolus Insulin or Fast-acting Insulin

  • Pre-mixed Insulin or Combination Insulin

  • Traditional Human Insulins

  • Traditional Human Insulin Biosimilars

  • Insulin Glargine Biosimilars

  • Non-Insulin Injectable

  • GLP-1 Agonist Market

  • Amylin Analogue

  • Oral Anti-diabetics Drugs

  • Dopamine-D2 Receptor Agonist

  • Meglitinide

  • Alpha-Glucosidase Inhibitors

  • SGLT2 Inhibitors

  • Biguanides

  • Sulfonylureas

  • DPP-4 Inhibitors

  • Combination Drugs

  • Insulin Combinations

  • Oral Combinations

  • Diabetes Device Categories

  • Management Devices

  • Insulin-delivery Devices

  • Insulin Syringes

  • Cartridges in Reusable Pens

  • Disposable Pens

  • Jet Injectors

  • Insulin Pump

  • Insulin Pump Devices

  • Insulin Pump Reservoirs

  • Infusion Sets

  • Monitoring Devices

  • Self-monitoring Blood Glucose Devices (SMBG)

By Component:

  • Glucometer Devices

  • Test Strips

  • Lancets

  • By End-user

  • Hospital

  • Glucometer Devices

  • Test Strips

  • Lancets

  • Personal

  • Glucometer Devices

  • Test Strips

  • Lancets

  • Continuous Glucose Monitoring Devices (CGM)

  • CGM durables (Receivers and Transmitters)

  • Sensors

Market Overview

The global diabetes care market is expected to grow because of the growing diabetes population levels and increasing diabetes expenditure in established, as well as pharm emerging countries.

Global Rise in Diabetic Population

  • There has been a tremendous increase in the global diabetic population levels over the past decade. Several reports and surveys documented a drastic increase in the diabetic population levels, based on the changing lifestyles and habits.

  • Extensive urbanization in various parts of the globe is considered to be the primary cause of obesity, health deterioration, physical inactivity, etc. Owing to these factors the prevalence of Type 2 Diabetes mellitus (T2DM) has increased significantly.

  • It is estimated that out of the total 415 million people suffering from diabetes worldwide, 46% of this demographic is those with undiagnosed diabetes.

  • The growing diabetic population levels act as a driver for insulin monitoring devices, such as glucometers, CGMs, etc. In developed countries, close to 90% of Type 1 Diabetic patients use glucometers. It is expected that during the forecast period close to 50% of Type 2 Diabetic patients will use a glucometer.

The United States Leads the Diabetes Drugs & Devices Market

  • In 2017, the US diabetes drugs market held the largest market share in North America, due to the presence of a high-quality healthcare system and increasing prevalence of diabetes in the region.

  • In the Asia-Pacific region, China and India have been identified as potential emerging markets, due to the rising diabetic population levels.

Reasons to Purchase this Dashboard

  • More Granular: Covers more categories, segments and brands' information at country- and global-levels compared to other market intelligence providers

  • Analyzing the outlook of the market with recent market data, historical data and market forecast

  • Ease of Comparability: Analytics are based on a standardized definition across the globe to facilitate better comparability of market data

  • View the market in different ways among categories and geography to understand where actual opportunities lie

  • Market segmentation including quantitative research, incorporating the impact of economic and non-economic aspects

  • Regional- and country-level data integrating the demand and supply forces which are influencing the growth of the market

  • Market value (in USD million) and volume data for each segment and sub-segment

  • Understanding of the market based on value and volume changes, intra category competition.

  • Dedicated analyst support for research queries and training

  • Continuous yearly amendment of the database with significant changes updated based on scenarios

Key Topics Covered:

1. Introduction

2. Research Approach and Methodology

3. Market Segmentation

3.1 By Drug

3.2 By Device

3.3 Geography

4. Market Indicators

5. Company Share Analysis

For more information about this report visit

View source version on

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting